CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.
Also called NCT05797792
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 440 participants
- Sponsor
- Registry
-
NCT05797792 -
2023-504262-32
-
- Other papers using this trial's data
- Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT05797792. Randomized; single masking; primary purpose treatment. Start 2023-11-18 (actual); primary completion 2025-08-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).
- Acronym
- CHOICE2
- Condition
- Stroke, Acute Ischemic
- Condition
- Stroke, Acute
- Intervention (Drug)
- Intraarterial alteplase
- Lead sponsor
- Hospital Clinic of Barcelona
Record details
- Record id
cardio:ct-nct05797792- Content hash
c87223e014596e5db4591438ebf2f5388ac8f831fdcca7656a574f29f62558b4